| 1362 |
National Cancer Institute |
Html |
en |
Hot Flashes and Night Sweats (PDQ®)–Health Professional Version |
Expert-reviewed information summary about causes and treatment of hot flashes and night sweats in cancer patients. |
| hot flash scores | 0.45918 |
| tamoxifen-induced hot flashes | 0.487401 |
| Loprinzi CL | 0.545839 |
| menopausal symptoms | 0.464059 |
| Barton DL | 0.475444 |
| nocturnal hot flashes | 0.494473 |
| black cohosh | 0.488248 |
| androgen deprivation therapy | 0.448869 |
| clinical trial | 0.448391 |
| breast cancer treatment | 0.460098 |
| breast cancer patients | 0.474226 |
| postmenopausal breast cancer | 0.456276 |
| hot flashes merits | 0.487946 |
| Natl Cancer Inst | 0.459556 |
| breast cancer survivors | 0.509665 |
| North Central Cancer | 0.472407 |
| hot flash reduction | 0.458714 |
| hot flashes | 0.905213 |
| hormone replacement therapy | 0.476539 |
| et al. | 0.506432 |
| women | 0.50642 |
| core body temperature | 0.45737 |
| night sweats | 0.457026 |
| study | 0.456946 |
| stage breast cancer | 0.454333 |
|
| hot flash studies | 0.449594 |
| hot flushes | 0.465978 |
| breast cancer diagnosis | 0.451556 |
| postmenopausal hot flashes | 0.500892 |
| breast cancer recurrence | 0.47207 |
| hot flash management. | 0.448239 |
| PUBMED Abstract | 0.549613 |
| Cancer Res Treat | 0.462211 |
| nighttime hot flashes | 0.501942 |
| hot flash frequency | 0.50736 |
| menopausal hot flashes | 0.487616 |
| Cancer Treatment Group | 0.476248 |
| hot flash management | 0.49365 |
| postmenopausal women | 0.477394 |
| breast cancer risk | 0.486953 |
| Clin Oncol | 0.505954 |
| receptor–positive breast cancer | 0.451466 |
| breast cancer | 0.743246 |
| randomized controlled trial | 0.545918 |
| hot flash | 0.591793 |
| healthy postmenopausal women | 0.454945 |
| prostate cancer | 0.455636 |
| placebo-controlled trial | 0.450402 |
| Central Cancer Treatment | 0.476295 |
|
CLICK HERE |
| 1452 |
National Cancer Institute |
Html |
en |
Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version |
Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking. |
| smoking cessation strategy | 0.633721 |
| smoking cessation rates | 0.605741 |
| quit attempt | 0.552085 |
| effective smoking cessation | 0.580922 |
| gradual cessation group | 0.483049 |
| abrupt cessation | 0.562882 |
| prolonged validated smoking | 0.480554 |
| lung cancer | 0.658405 |
| tobacco cessation | 0.463262 |
| smoking cessation pharmacotherapies | 0.597527 |
| abrupt smoking cessation | 0.601297 |
| pipe tobacco smoking | 0.505275 |
| current smoking | 0.475722 |
| gradual cessation arm | 0.465437 |
| nicotine replacement therapy | 0.54532 |
| randomized trial | 0.492165 |
| Smoking cessation counseling | 0.609156 |
| receptor partial agonist | 0.460896 |
| area-level smoking prevalence | 0.513667 |
| smoking reduction | 0.49426 |
| smoking behavior | 0.469981 |
| smoking cessation treatment | 0.588411 |
| smoking prevalence data | 0.513642 |
| tobacco products | 0.485537 |
|
| abrupt cessation arm | 0.472163 |
| smoking cessation | 0.926558 |
| vs abrupt cessation | 0.475821 |
| adult cigarette smoking | 0.474818 |
| gradual cessation method | 0.466403 |
| cigarette smoking cessation | 0.573293 |
| cigarette smoking | 0.62168 |
| smoking cessation pharmacotherapy | 0.595082 |
| varenicline | 0.542592 |
| tobacco smoking | 0.505702 |
| smoking cessation rate. | 0.602815 |
| gradual cessation | 0.501212 |
| abrupt cessation group | 0.489713 |
| nicotinic acetylcholine receptor | 0.464069 |
| self-reported smoking abstinence | 0.502629 |
| smoking abstinence | 0.574891 |
| cigarette smoking prevalence | 0.566333 |
| randomized controlled trial | 0.482431 |
| 6-month cessation rates | 0.474432 |
| nicotine patch | 0.531368 |
| smoking cessation intervention | 0.590903 |
| usual smoking patterns | 0.480697 |
| lung cancer mortality | 0.510576 |
| varenicline group | 0.534998 |
|
CLICK HERE |
| 1610 |
National Cancer Institute |
Html |
en |
Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version |
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are composed of three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). Learn about the clinical features and treatment of these leukemias. |
| JMML | 0.47142 |
| 5-year estimated probability | 0.444988 |
| evidence | 0.458611 |
| host disease grade | 0.440441 |
| anemia supervenes | 0.445725 |
| various chemotherapy regimens | 0.572089 |
| platelet-derived growth factor | 0.511436 |
| Leukemia Group | 0.448642 |
| white blood cells | 0.44993 |
| Myelodysplastic/ Myeloproliferative Neoplasms | 0.440718 |
| CMML | 0.717566 |
| marrow stem cell | 0.463204 |
| myelomonocytic leukemia | 0.462437 |
| HLA-matched unrelated individuals | 0.444789 |
| toxic effects | 0.442066 |
| bone marrow aplasia | 0.560704 |
| chronic myelomonocytic leukemia | 0.449424 |
| transplant-related mortality | 0.457149 |
| World Health Organization | 0.564993 |
| erythropoietic growth factors | 0.554859 |
| median age | 0.543021 |
| level | 0.460994 |
| randomized trial | 0.458448 |
| patients | 0.901262 |
| monthly maintenance | 0.44579 |
|
| randomized clinical trial | 0.484352 |
| major defining feature | 0.454521 |
| complete remission | 0.448646 |
| proliferative features | 0.448887 |
| DNA methyltransferase | 0.449167 |
| et al. | 0.534469 |
| young MDS patients | 0.511634 |
| follow-up study | 0.441281 |
| Complete hematologic remissions | 0.570636 |
| JMML leukemia cells | 0.462656 |
| pyrimidine-analog antimetabolite | 0.44631 |
| stem cell | 0.531211 |
| single-agent therapy | 0.444312 |
| 13-cis retinoic acid | 0.524469 |
| transfusion requirements | 0.448178 |
| Median actuarial survival | 0.504944 |
| median duration | 0.676959 |
| nucleoside azacitidine | 0.478539 |
| particularly poor prognosis. | 0.444869 |
| patient survival data. | 0.445943 |
| bone marrow | 0.729115 |
| total-body radiation therapy | 0.553338 |
| allogeneic stem cell | 0.441128 |
| Juvenile myelomonocytic leukemia | 0.458499 |
|
CLICK HERE |
| 1773 |
National Cancer Institute |
Html |
es |
Trastornos del sueño (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las causas de los trastornos del sueño de las personas con cáncer y su manejo. |
| American Academy | 0.62007 |
| sleep disturbance | 0.546203 |
| Sateia MJ | 0.426893 |
| Sleep Disturbance Scale | 0.434259 |
| CdV Mejoras | 0.428861 |
| mg riesgo | 0.50361 |
| National Sleep Foundation | 0.473914 |
| Sleep Quality Index | 0.466452 |
| Simard S | 0.452533 |
| neglected problem | 0.428741 |
| sueño mor | 0.943385 |
| risk factors | 0.426951 |
| sleep-wake disturbances | 0.458084 |
| Sleep Disorders | 0.45951 |
| Oncol Nurs | 0.45478 |
| PDQ Delirium | 0.436712 |
| coordinación motriz | 0.436956 |
| sueño diario | 0.570793 |
| sleep disruption | 0.458489 |
| Insomnia Severity Index | 0.446987 |
| patients with | 0.455594 |
| Hirshkowitz M | 0.42487 |
| Pittsburgh Sleep Quality | 0.464939 |
| Insomnia Severity | 0.454434 |
| sueño frente | 0.501612 |
|
| Roscoe JA | 0.426353 |
| Oncol Nurs Forum | 0.453234 |
| Morin CM | 0.426813 |
| sueño categorÃa | 0.493243 |
| Care Cancer | 0.439262 |
| Palesh OG | 0.427427 |
| ECA Control | 0.495325 |
| Savard J | 0.54747 |
| Sleep Medicine review | 0.435342 |
| Mustian KM | 0.426387 |
| patients based | 0.427546 |
| Rochester Cancer Center-Community | 0.462263 |
| Clinical Oncology Program | 0.450218 |
| sleep regulation | 0.427006 |
| sueño nmor | 0.697198 |
| Clin Oncol | 0.506515 |
| Clin North Am | 0.455007 |
| estadio i–iii | 0.467766 |
| Center-Community Clinical Oncology | 0.451231 |
| psychological associations | 0.42745 |
| Cancer Center-Community Clinical | 0.464249 |
| Sleep Medicine | 0.709305 |
| Med Clin North | 0.456379 |
| Sleep Disorders Classification | 0.439634 |
|
CLICK HERE |
| 1927 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil. |
| siguientes procedimientos | 0.539535 |
| células madre | 0.949818 |
| estadio iv | 0.500925 |
| adultos jóvenes | 0.452563 |
| órgano cercano.ampliar linfoma | 0.561365 |
| siguientes elementos | 0.448931 |
| sudores nocturnos | 0.484622 |
| faja ajustadora | 0.430459 |
| siguientes especialistas | 0.43177 |
| siguientes tipos | 0.443725 |
| vÃa oral | 0.419326 |
| rayos x | 0.473568 |
| Hodgkin Lymphoma | 0.582459 |
| abdomen).ampliar linfoma | 0.535694 |
| detecte.ampliar exploración | 0.434601 |
| enlace drugs approved | 0.498183 |
| escáner tep | 0.492453 |
| niño ayuda | 0.424524 |
| estadio iiies | 0.760474 |
| riesgo intermedio | 0.462626 |
| efectos tardÃos | 0.664689 |
| estadio ie | 0.575058 |
| células anormales.ampliar aspiración | 0.485872 |
|
| PDQ Efectos tardÃos | 0.461638 |
| National Cancer Institute | 0.420283 |
| sustancia quizás | 0.427861 |
| siguientes lugares | 0.433237 |
| siguientes riesgos | 0.418851 |
| Instituto Nacional | 0.434896 |
| PDQ Tratamiento | 0.682769 |
| estadio iie | 0.500587 |
| Hodgkin recién | 0.557678 |
| explorador tep | 0.443167 |
| estadio e | 0.45134 |
| nuevos tipos | 0.421275 |
| Physician Data Query | 0.471298 |
| posibles efectos | 0.420063 |
| infancia quizás | 0.428464 |
| estadio iiis | 0.959473 |
| ósea fabrica glóbulos | 0.493208 |
| pelvis.ampliar imágenes | 0.420331 |
| distinta intensidad | 0.419212 |
| almacena células | 0.485736 |
| siguientes pruebas | 0.485604 |
| siguientes estadios | 0.440037 |
|
CLICK HERE |
| 2114 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de hígado (hepatocelular) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de hígado (hepatocelular). |
| hepatitis c | 0.799278 |
| PDQ Exámenes | 0.723065 |
| estudio marcadores | 0.652784 |
| siguientes efectos | 0.659695 |
| Physician Data Query | 0.826748 |
| Estados Unidos | 0.932003 |
| rayos x | 0.659043 |
| prevención revisa | 0.639071 |
| sustancias dañinas | 0.671115 |
|
| cuerpo usa | 0.666699 |
| ondas sonoras | 0.6623 |
| siguientes exámenes | 0.740755 |
| información ayuda | 0.645281 |
| National Cancer Institute | 0.657644 |
| siguientes riesgos | 0.650336 |
| siguientes sumarios | 0.743208 |
| Instituto Nacional | 0.706872 |
| múltiples funciones | 0.667669 |
|
CLICK HERE |
| 3446 |
National Cancer Institute |
Html |
es |
Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el abandono del tabaquismo. |
| efectos secundarios comentarios | 0.501986 |
| leucemia mieloide | 0.427415 |
| metabolitos carcinógenos | 0.42791 |
| bupropión marca dosis | 0.454219 |
| grupo vareniclina | 0.463468 |
| importancia clÃnica | 0.450606 |
| MVL Nicorette DS | 0.439222 |
| pruebas directas | 0.619014 |
| MVL Nicoderm CQ | 0.440426 |
| MVL Commit | 0.42718 |
| Sin embargo | 0.467903 |
| muertes prematuras | 0.469229 |
| largo plazo | 0.764238 |
| cessation interventions among | 0.449671 |
| Lung Health Study | 0.44169 |
| Lancaster T | 0.545862 |
| defunciones prematuras | 0.434559 |
| bupropión mejora | 0.45245 |
| Stead LF | 0.482703 |
| orientación mejora | 0.429664 |
| bupropión ap | 0.446903 |
| Nicotine replacement therapy | 0.444158 |
| semanas insomnio | 0.443481 |
| vareniclina mejora | 0.477582 |
| Estados Unidos | 0.989049 |
|
| polacrilex marca dosis | 0.434801 |
| insomnio riesgo | 0.427937 |
| smoking cessation | 0.872626 |
| salud pública | 0.590985 |
| Database Syst Rev | 0.689429 |
| abandono gradual versus | 0.477395 |
| nicotina marca dosis | 0.473496 |
| beneficio hipotético implÃcito | 0.443214 |
| Treating Tobacco Use | 0.44172 |
| versus trn | 0.451335 |
| MVL Nicorette | 0.462807 |
| mejores tasas | 0.435725 |
| Community Intervention Trial | 0.530278 |
| Marca Dosis Efectos | 0.591077 |
| alta calidad | 0.516955 |
| efectos secundarios advertencias | 0.436485 |
| compuestos carcinógenos | 0.426773 |
| tasas promedio | 0.433836 |
| aductos carcinógenos | 0.42846 |
| planta cytisus laburnum | 0.434664 |
| antidepresivo bupropión | 0.449342 |
| cuello uterino | 0.576293 |
| MVL Nicotrol | 0.425887 |
| Surveillance Modeling Network | 0.440037 |
|
CLICK HERE |
| 3523 |
National Cancer Institute |
Html |
es |
Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos) |
Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento. |
| Tumor Profiling | 0.554625 |
| estudio match | 0.941659 |
| Investigación Oncológica | 0.6022 |
| MD Anderson | 0.61416 |
| Memorial Sloan-Kettering Cancer | 0.578519 |
| Clinical Trials | 0.539697 |
| posibles participantes | 0.607033 |
| C2 MET | 0.546519 |
| Life Sciences | 0.627896 |
| laboratorios foundation medicine | 0.56991 |
| Foundation Medicine | 0.623082 |
| Memorial Sloan-Kettering identificarán | 0.577406 |
| estudio comet | 0.807536 |
| Grupo Cambio | 0.537516 |
| met amp crizotinib | 0.576245 |
|
| como los costos | 0.539059 |
| seguro médico | 0.533808 |
| Cancer Center | 0.605302 |
| MD Anderson Cancer | 0.572606 |
| tratamiento inscribirán | 0.618222 |
| sk crizotinib | 0.541473 |
| cabo estudios | 0.534561 |
| Caris Life Sciences | 0.579205 |
| Investigación Oncológica ECOG-ACRIN | 0.571301 |
| Memorial Sloan-Kettering | 0.625566 |
| egfr mut afatinib | 0.573282 |
| NRG Oncology Group | 0.568484 |
| Iniciativa de Medicina | 0.538366 |
| Life Sciences identificarán | 0.57351 |
|
CLICK HERE |
| 3573 |
National Cancer Institute |
Html |
en |
Immunotherapy: Using the Immune System to Treat Cancer |
Immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against tumors. |
| abnormal cells | 0.352853 |
| CAR T cells | 0.324531 |
| cancer cells | 0.817652 |
| immune system activity | 0.227645 |
| immune responses | 0.409806 |
| toxic substance | 0.204832 |
| dendritic cells | 0.272111 |
| immune system molecules | 0.223265 |
| white blood cells | 0.307219 |
| activated T cells | 0.296761 |
| immune system—research | 0.253725 |
| immune response | 0.250155 |
| advanced lung cancer | 0.212796 |
| cancer treatment vaccine | 0.201283 |
| clinical trials | 0.278634 |
| tumor cells | 0.49599 |
| CD20-expressing cells | 0.269956 |
| normal cells | 0.295119 |
| human clinical trials | 0.248944 |
|
| antibody-dependent cell-mediated cytotoxicity | 0.250246 |
| patients | 0.23385 |
| advanced melanoma | 0.22903 |
| immune cells | 0.680701 |
| immune checkpoint inhibitors | 0.313495 |
| FDA-approved checkpoint inhibitors | 0.216978 |
| therapeutic antibodies | 0.216622 |
| cancer cell death | 0.250231 |
| immunotherapy uses proteins | 0.212508 |
| CAR T-cell therapy | 0.397055 |
| natural killer cells | 0.304861 |
| lymphoma cells | 0.266327 |
| cells | 0.903811 |
| different checkpoint protein | 0.207351 |
| modified T cells | 0.282987 |
| immune checkpoint proteins | 0.3798 |
| existing T cells | 0.321978 |
| certain immune cells | 0.38886 |
|
CLICK HERE |
| 15802 |
National Cancer Institute |
Html |
null |
About the Blue Ribbon Panel |
Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science. |
|
|
CLICK HERE |